MEDIANTECHNOLOGIES overview

Regulatory News: Median Technologies ( FR0011049824, ALMDT , PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today reported its 2024 consolidated annual financial results, as of December 31, 2024. The consolidated financial...

Regulatory News: Median Technologies ( FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, releases today its Q1 2025 key financial indicators (unaudited) and provides an update on Q1 operational achievements....

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,859,216 Number of real voting rights* (excluding treasury shares**) 18,785,889 Theoretical number of voting rights* (including treasury shares**) 18,836,016 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to...

Regulatory News: Median Technologies (Paris:ALMDT) ( FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, disclosed today pivotal study RELIVE’s final results, which confirm and complement the top-line results...

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,757,159 Number of real voting rights* (excluding treasury shares**) 18,695,888 Theoretical number of voting rights* (including treasury shares**) 18,733,959 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to...

Regulatory News: The shareholders of Median Technologies ( FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) are invited to participate in the Shareholders’ Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website. Shareholders may exercise their voting...

Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”) , a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45 th Annual Health Care Conference, taking place March 3-5...

Regulatory News: Median Technologies ( FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”) , a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March...